You are here

Article Text

Article menu
Download PDFPDF
Editorial commentary
Is it time to consider rationalising IFN-β treatment in individuals with multiple sclerosis?

https://doi.org/10.1136/jnnp.2004.046342

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Conflict of interests: I have participated in meetings sponsored by and received honoraria from pharmaceutical companies marketing treatments for MS. I have or am participating in randomised controlled trials involving IFN-β-1b (Betaferon®, Schering), IFN-β-1a (Avonex®, Biogen), and Natalizumab (Antegren®, Biogen-Idec/Elan) in MS. I have also received honoraria for acting in the capacity as an advisor to various pharmaceutical companies who have drug development programmes for MS.